Potential Weight Loss Pill Promises Fat Reduction Without hunger Control

Potential Weight Loss Pill Promises Fat Reduction Without hunger Control

Hey there! Let's talk about this new experimental obesity pill called SANA. Unlike popular GLP-1 drugs like Ozempic, SANA doesn't mess with your appetite—instead, it torchers off some energy and fat! That's right, SANA kicks off a process called creatine-dependent thermogenesis, which burns energy and helps maintain a stable internal temperature[1][2]. Interesting, huh?

So here's the deal: In a preliminary human trial, SANA led to statistically significant weight loss after just two weeks[3]. The drug is based on salicylate, a compound found in aspirin, and it's developed by Eolo Pharma, a cool company hailing from Montevideo, Uruguay.

Now, you might be wondering, "But how does this creatine-dependent thermogenesis work?" Well, creatine isn't just a nutritional supplement for building muscle mass after a workout; it's also crucial for energy production in the human body[1].

Back in the 1970s, researchers discovered that rats exposed to cold used a bunch of creatine, and in the early 2000s, a Harvard team found that creatine is useful for fatty adipose tissue during cold exposure to generate heat[1][2].

In a trial involving 41 participants (27 healthy-weight individuals and 14 with obesity), they tested SANA at different doses.You guessed it—the higher the dose, the greater the weight loss! The participants on the highest dose lost about 3% of their body weight, which is impressive considering that's similar to the weight loss seen with Ozempic and Wegovy over the same period[3]. But here's the best part: none of the SANA participants reported a decrease in either appetite or feelings of satiety[3].

Now, you might already be familiar with GLP-1 drugs like Ozempic, which reduce food intake by stimulating feelings of fullness[4]. These drugs hit the brain and gut to promote feelings of satiety and slow down the movement of food through the stomach, but they can cause gastrointestinal side effects and lead to muscle wastage[4]. Plus, they're quite pricey, often costing a whopping $1,000 a month or more in the US.

Since SANA works differently, some drug companies are eager to develop it as an affordable anti-obesity pill that patients might prefer over injectables[4].

So, is the future of obesity treatment about burning energy and fat instead of playing mind games with our appetites? Time will tell, but SANA is definitely shaking things up in the weight loss world!

1. The new experimental obesity pill SANA, developed by Eolo Pharma, doesn't manipulate appetite like GLP-1 drugs; instead, it utilizes creatine-dependent thermogenesis to burn energy and fat.
2. In a preliminary human trial, SANA led to statistically significant weight loss after just two weeks, with the participants on the highest dose losing about 3% of their body weight, a level similar to that seen with GLP-1 drugs Ozempic and Wegovy.
3. Unlike GLP-1 drugs, SANA doesn't cause a decrease in appetite or feelings of satiety, making it potentially more appealing to patients.
4. Creatine, a compound found in aspirin, is not only used as a nutritional supplement for building muscle mass but also plays a crucial role in energy production in the human body.
5. As SANA works differently from traditional GLP-1 drugs, some drug companies are interested in developing it as an affordable anti-obesity pill, possibly disrupting the current weight loss market.

Read also: